Skip to content
10-K

Annual Report

Allarity Therapeutics, Inc. ALLR

0001437749-26-010310

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 30, 2026 15.82M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $3.19M
Stock Repurchased FY 2025 · Dec 31, 2024 $0
Capex FY 2025 · Dec 31, 2025 $8K
Capex FY 2025 · Dec 31, 2024 $298K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$14.82M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$17.35M
Cash And Equivalents FY 2025 · Dec 31, 2025 $14.69M
Cash And Equivalents FY 2025 · Dec 31, 2024 $19.53M
Stockholders Equity FY 2025 · Dec 31, 2025 $9.83M
Stockholders Equity FY 2025 · Dec 31, 2024 $11.81M
Stockholders Equity FY 2025 · Dec 31, 2023 −$2.75M
Current Liabilities FY 2025 · Dec 31, 2025 $8.43M
Current Liabilities FY 2025 · Dec 31, 2024 $10.84M
Total Liabilities FY 2025 · Dec 31, 2025 $8.43M
Total Liabilities FY 2025 · Dec 31, 2024 $10.84M
Current Assets FY 2025 · Dec 31, 2025 $17.93M
Current Assets FY 2025 · Dec 31, 2024 $22.34M
Total Assets FY 2025 · Dec 31, 2025 $18.26M
Total Assets FY 2025 · Dec 31, 2024 $22.65M
Eps Basic FY 2025 · Dec 31, 2025 −$0.78
Eps Basic FY 2025 · Dec 31, 2024 −$15.65
Sga Expense FY 2025 · Dec 31, 2025 $6.32M
Sga Expense FY 2025 · Dec 31, 2024 $11.44M
Rd Expense FY 2025 · Dec 31, 2025 $6.6M
Rd Expense FY 2025 · Dec 31, 2024 $6.1M
Net Income FY 2025 · Dec 31, 2025 −$11.23M
Net Income FY 2025 · Dec 31, 2024 −$24.52M
Operating Income FY 2025 · Dec 31, 2025 −$12.61M
Operating Income FY 2025 · Dec 31, 2024 −$27.24M
Revenue FY 2025 · Dec 31, 2025 $320K
Revenue FY 2025 · Dec 31, 2024 $0